Ubiquitination and degradation of mutant p53

Molecular and Cellular Biology

Volumn 27, Issue 23, 2007, Pages 8284-8295

  Lukashchuk, Natalia ^a   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C TERMINUS OF HSC70 INTERACTING PROTEIN; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; UBIQUITINATION;

ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 36849035345     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00050-07     Document Type: Article

References (69)

1. Alarcon-Vargas, D., and Z. Ronai. 2002. p53-Mdm2: the affair that never ends. Carcinogenesis 23:541-547.
2. Ashcroft, M., M. H. Kubbutat, and K. H. Vousden. 1999. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19:1751-1758.
3. Boyd, S. D., K. Y. Tsai, and T. Jacks. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563-568.
4. Brignone, C., K. E. Bradley, A. F. Kisselev, and S. R. Grossman. 2004. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene 23:4121-4129.
5. Bullock, A. N., and A. R. Fersht. 2001. Rescuing the function of mutant p53. Nat. Rev. Cancer 1:68-76.
6. Buschmann, T., T. Minamoto, N. Wagle, S. Y. Fuchs, V. Adler, M. Mai, and Z. Ronai. 2000. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J. Mol. Biol. 295:1009-1021.
7. Cadwell, C., and G. P. Zambetti. 2001. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30.
8. Carter, S., O. Bischof, A. Dejean, and K. H. Vousden. 2007. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9:428-435.
9. Ceskova, P., H. Chichger, M. Wallace, B. Vojtesek, and T. R. Hupp. 2006. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. J. Mol. Biol. 357:442-456.
10. Chen, D., N. Kon, M. Li, W. Zhang, J. Qin, and W. Gu. 2005. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121:1071-1083.
11. Chen, J., J. Lin, and A. J. Levine. 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:142-152.
12. Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
13. Corcoran, C. A., Y. Huang, and M. S. Sheikh. 2004. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol. Ther. 3:721-725.
14. Dornan, D., I. Wertz, H. Shimizu, D. Arnott, G. D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, and V. M. Dixit. 2004. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429:86-92.
15. Esser, C., M. Scheffner, and J. Hohfeld. 2005. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280:27443-27448.
16. Fang, S., J. P. Jensen, R. L. Ludwig, K. H. Vousden, and A. M. Weissman. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:8945-8951.
17. Finlay, C. A., P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:531-539.
18. Geyer, R. K., Z. K. Yu, and C. G. Maki. 2000. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:569-573.
19. Glockzin, S., F. X. Ogi, A. Hengstermann, M. Scheffner, and C. Blattner. 2003. Involvement of the DNA repair protein hHR23 in p53 degradation. Mol. Cell. Biol. 23:8960-8969.
20. Gu, J., L. Nie, D. Wiederschain, and Z. M. Yuan. 2001. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol. Cell. Biol. 21:8533-8546.
21. Harms, K. L., and X. Chen. 2006. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 13:890-897.
22. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
23. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
24. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
25. Jiang, J., C. A. Ballinger, Y. Wu, Q. Dai, D. M. Cyr, J. Hohfeld, and C. Patterson. 2001. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276:42938-42944.
26. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
27. Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
28. Kubbutat, M. H., R. L. Ludwig, M. Ashcroft, and K. H. Vousden. 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18:5690-5698.
29. Kubbutat, M. H., R. L. Ludwig, A. J. Levine, and K. H. Vousden. 1999. Analysis of the degradation function of Mdm2. Cell Growth Differ. 10:87-92.
30. Kulikov, R., M. Winter, and C. Blattner. 2006. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J. Biol. Chem. 281:28575-28583.
31. Lang, G. A., T. Iwakuma, Y. A. Suh, G. Liu, V. A. Rao, J. M. Parant, Y. A. Valentin-Vega, T. Terzian, L. C. Caldwell, L. C. Strong, A. K. El-Naggar, and G. Lozano. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872.
32. Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-791.
33. Lohrum, M. A., D. B. Woods, R. L. Ludwig, E. Balint, and K. H. Vousden. 2001. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 21:8521-8532.
34. Lowe, S. W., and C. J. Sherr. 2003. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13:77-83.
35. Maki, C. G. 1999. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem. 274:16531-16535.
36. Marston, N. J., T. Crook, and K. H. Vousden. 1994. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9:2707-2716.
37. Marston, N. J., J. R. Jenkins, and K. H. Vousden. 1995. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10:1709-1715.
38. Michael, D., and M. Oren. 2003. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13:49-58.
39. Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189.
40. Moll, U. M., and O. Petrenko. 2003. The MDM2-p53 interaction. Mol. Cancer Res. 1:1001-1008.
41. Momand, J., H. H. Wu, and G. Dasgupta. 2000. MDM2: master regulator of the p53 tumor suppressor protein. Gene 242:15-29.
42. Nie, L., M. Sasaki, and C. G. Maki. 2007. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J. Biol. Chem. 282:14616-14625.
43. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
44. Olive, K. P., D. A. Tuveson, Z. C. Ruhe, B. Yin, N. A. Willis, R. T. Bronson, D. Crowley, and T. Jacks. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860.
45. Peng, Y., L. Chen, C. Li, W. Lu, and J. Chen. 2001. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J. Biol. Chem. 276:40583-40590.
46. Rajendra, R., D. Malegaonkar, P. Pungaliya, H. Marshall, Z. Rasheed, J. Brownell, L. F. Liu, S. Lutzker, A. Saleem, and E. H. Rubin. 2004. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J. Biol. Chem. 279:36440-36444.
47. Rogel, A., M. Popliker, C. G. Webb, and M. Oren. 1985. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol. 5:2851-2855.
48. Sdek, P., H. Ying, D. L. Chang, W. Qiu, H. Zheng, R. Touitou, M. J. Allday, and Z. X. Xiao. 2005. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20:699-708.
49. Shimizu, H., L. R. Burch, A. J. Smith, D. Dornan, M. Wallace, K. L. Ball, and T. R. Hupp. 2002. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277:28446-28458.
50. Shimizu, H., D. Saliba, M. Wallace, L. Finlan, P. R. Langridge-Smith, and T. R. Hupp. 2006. Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem. J. 397:355-367.
51. Sigal, A., and V. Rotter. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60:6788-6793.
52. Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952.
53. Soussi, T., and G. Lozano. 2005. p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun. 331:834-842.
54. Tang, J., L. K. Qu, J. Zhang, W. Wang, J. S. Michaelson, Y. Y. Degenhardt, W. S. El-Deiry, and X. Yang. 2006. Critical role for Daxx in regulating Mdm2. Nat. Cell Biol. 8:855-862.
55. Uchida, C., S. Miwa, K. Kitagawa, T. Hattori, T. Isobe, S. Otani, T. Oda, H. Sugimura, T. Kamijo, K. Ookawa, H. Yasuda, and M. Kitagawa. 2005. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24:160-169.
56. Uldrijan, S., W. J. Pannekoek, and K. H. Vousden. 2007. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 26:102-112.
57. Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
58. Vousden, K. H. 2002. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602:47-59.
59. Vousden, K. H. 2006. Outcomes of p53 activation: spoilt for choice. J. Cell Sci. 119:5015-5020.
60. Wallace, M., E. Worrall, S. Pettersson, T. R. Hupp, and K. L. Ball. 2006. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23:251-263.
61. Webley, K. M., A. J. Shorthouse, and J. A. Royds. 2000. Effect of mutation and conformation on the function of p53 in colorectal cancer. J. Pathol. 191:361-367.
62. Weger, S., E. Hammer, and R. Heilbronn. 2002. Topors, a p53 and topoisomerase I binding protein, interacts with the adeno-associated virus (AAV-2) Rep78/68 proteins and enhances AAV-2 gene expression. J. Gen. Virol. 83:511-516.
63. Whitesell, L., P. D. Sutphin, E. J. Pulcini, J. D. Martinez, and P. H. Cook. 1998. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol. 18:1517-1524.
64. Wong, K. B., B. S. DeDecker, S. M. Freund, M. R. Proctor, M. Bycroft, and A. R. Fersht. 1999. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96:8438-8442.
65. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
66. Yamasaki, S., N. Yagishita, T. Sasaki, M. Nakazawa, Y. Kato, T. Yamadera, E. Bae, S. Toriyama, R. Ikeda, L. Zhang, K. Fujitani, E. Yoo, K. Tsuchimochi, T. Ohta, N. Araya, H. Fujita, S. Aratani, K. Eguchi, S. Komiya, I. Maruyama, N. Higashi, M. Sato, H. Senoo, T. Ochi, S. Yokoyama, T. Amano, J. Kim, S. Gay, K. Nishioka, A. Hukamizu, K. Tanaka, and T. Nakajima. 2006. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 26:113-122.
67. Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444-452.
68. Yu, G. W., S. Rudiger, D. Veprintsev, S. Freund, M. R. Fernandez-Fernandez, and A. R. Fersht. 2006. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. USA 103:1227-1232.
69. Zhu, Q., J. Yao, G. Wani, M. A. Wani, and A. A. Wani. 2001. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis. J. Biol. Chem. 276:29695-29701.